Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia

Nephron - Physiology

Volumn 108, Issue 4, 2008, Pages

  Sánchez Lozada, Laura G ^a   Tapia, Edilia ^a   Soto, Virgilia ^a   Ávila Casado, Carmen ^a   Franco, Martha ^a   Wessale, Jerry L ^b   Zhao, Lin ^b   Johnson, Richard J ^c  

^a INC Ignacio Chavez ^*  (Mexico)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Arteriolopathy; Chronic renal damage; Febuxostat; Glomerular hypertension; Hyperuricemia; Micropuncture

Indexed keywords

FEBUXOSTAT; OXONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLOMERULAR STRUCTURE; HEMODYNAMICS; HISTOPATHOLOGY; HYPERURICEMIA; KIDNEY; KIDNEY DISEASE; KIDNEY INJURY; MALE; MEASUREMENT; MORPHOLOGY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; VASOCONSTRICTION;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERURICEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MICROCIRCULATION; NEPHRECTOMY; OXONIC ACID; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; THIAZOLES; TREATMENT OUTCOME;

EID: 43949115923     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127837     Document Type: Article

References (34)

1. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-464.
2. McBride MB, Rigden S, Haycock GB, Dalton N, Van't HW, Rees L, Raman GV, Moro F, Ogg CS, Cameron JS, Simmonds HA: Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children. Pediatr Nephrol 1998;12:357-364.
3. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH: Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20.
4. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-650.
5. Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-150.
6. Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY: Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006;47:962-967.
7. Syamala S, Li J, Shankar A: Association between serum uric acid and prehypertension among US adults. J Hypertens 2007;25:1583-1589.
8. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980;93:817-821.
9. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-59.
10. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
11. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-1233.
12. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystalin-dependent mechanism. Hypertension 2001;38:1101-1106.
13. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997.
14. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001;71:900-905.
15. Sanchez-Lozada LG, Tapia E, vila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002;283:F1105-F1110.
16. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-247.
17. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.
18. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N: Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a 28-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-923.
19. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA: Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-1847.
20. Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, Komoriya K: Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993;241:183-188.
21. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-1855.
22. Henry RJ, Sobel Ch, Segalove M: Turbidimetric determination of proteins with sulfosalicylic and trichloroacetic acids. Proc Soc Exp Biol Med 1956;92:748-751.
23. Davidson WD, Sackner MA: Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 1963;62:351-356.
24. Vurek G, Pegram S: Fluorometric method for the determination of nanogram quantities of inulin. Ann Biochem 1966;16:409-419.
25. Viets JW, Deen WM, Troy JL, Brenner BM: Determination of serum protein concentration in nanoliter blood samples using fluorescamine or 9-phthalaldehyde. Anal Biochem 1978;88:513-521.
26. Baylis C, Deen WM, Myers BD, Brenner BM: Effects of some vasodilator drugs on transcapillary fluid exchange in renal cortex. Am J Physiol 1976;230:1148-1158.
27. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897.
28. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.
29. Pelayo JC, Shanley PF: Glomerular and tubular adaptive responses to acute nephron loss in the rat. Effect of prostaglandin synthesis inhibition. J Clin Invest 1990;85:1761-1769.
30. Sanchez-Lozada LG, Tapia E, Johnson RJ, Rodriguez-Iturbe B, Herrera-Acosta J: Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl 2003;S9-S14.
31. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricemia. Nephrol Dial Transplant 2008;23:1179-1185.
32. Kretschmer BD, Schelling P, Beier N, Liebscher C, Treutel S, Kruger N, Scholz HP, Haus A: Modulatory role of food, feeding regime and physical exercise on body weight and insulin resistance. Life Sci 2005;76:1553-1573.
33. Hayslett JP: Functional adaptation to reduction in renal mass. Physiol Rev 1979;59:137-164.
34. Gilbert RM, Weber H, Turchin L, Fine LG, Bourgoignie JJ, Bricker NS: A study of the intrarenal recycling of urea in the rat with chronic experimental pyelonephritis. J Clin Invest 1976;58:1348-1357.